We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+11.86%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$107M
Cap. Flow
+$91.9M
Cap. Flow %
23.24%
Top 10 Hldgs %
65.16%
Holding
37
New
10
Increased
12
Reduced
2
Closed
12

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$24.2M
2
INSP icon
Inspire Medical Systems
INSP
+$20.8M
3
ARGX icon
argenx
ARGX
+$17.8M
4
PFE icon
Pfizer
PFE
+$16.4M
5
ASND icon
Ascendis Pharma A/S
ASND
+$15.7M

Top Sells

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$19.9M
2
MRK icon
Merck
MRK
+$15.7M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
BAX icon
Baxter International
BAX
+$13.6M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$37.3B
$41.4M 10.48%
2,550,307
+334,119
+15% +$5.15M
ARGX icon
2
argenx
ARGX
$53.8B
$32.1M 8.11%
74,558
+46,577
+166% +$17.8M
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$31.1M 7.85%
227,762
+115,092
+102% +$15.7M
AMGN icon
4
Amgen
AMGN
$198B
$25.7M 6.5%
+82,271
New +$24.2M
NTRA icon
5
Natera
NTRA
$38.9B
$25M 6.31%
230,585
+40,471
+21% +$4.11M
AXSM icon
6
Axsome Therapeutics
AXSM
$11.8B
$24.7M 6.24%
306,513
+203,802
+198% +$15.1M
INSM icon
7
Insmed
INSM
$23.5B
$21.2M 5.36%
+316,501
New +$12.3M
MRUS
8
DELISTED
Merus
MRUS
$19.9M 5.02%
335,514
+49,192
+17% +$2.38M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$70.9B
$18.4M 4.65%
17,516
+8,949
+104% +$8.68M
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.8B
$18.3M 4.63%
65,352
+11,997
+22% +$2.86M
INSP icon
11
Inspire Medical Systems
INSP
$1.46B
$17.8M 4.51%
133,276
+109,710
+466% +$20.8M
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$16.7M 4.23%
1,189,518
+7
+0% +$114
PFE icon
13
Pfizer
PFE
$143B
$16.7M 4.22%
+596,919
New +$16.4M
UTHR icon
14
United Therapeutics
UTHR
$22.7B
$16M 4.04%
+50,100
New +$13.3M
LEGN icon
15
Legend Biotech
LEGN
$4.31B
$15.8M 3.99%
356,532
+72,759
+26% +$3.36M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$35.7B
$10.9M 2.76%
+45,000
New +$7.1M
STVN icon
17
Stevanato
STVN
$5.23B
$10.4M 2.62%
+565,422
New +$13.2M
NVO
18
Novo Nordisk
NVO
$223B
$9.11M 2.3%
+63,811
New +$8.46M
PCVX icon
19
Vaxcyte
PCVX
$8.12B
$8.56M 2.16%
+113,344
New +$7.72M
XENE icon
20
Xenon Pharmaceuticals
XENE
$6.6B
$3.98M 1.01%
101,959
-105,506
-51% -$4.22M
OCUL icon
21
Ocular Therapeutix
OCUL
$1.96B
$3.52M 0.89%
+514,642
New +$3.18M
PRAX icon
22
Praxis Precision Medicines
PRAX
$8.77B
$3.12M 0.79%
75,319
-31,175
-29% -$1.47M
DFTX
23
Definium Therapeutics
DFTX
$5.88B
$2.75M 0.7%
382,055
+2,459
+0.6% +$21.5K
KRRO icon
24
Korro Bio
KRRO
$177M
$2.42M 0.61%
+71,428
New +$3.95M
FEMY icon
25
Femasys
FEMY
$9.09M
$34.9K 0.01%
1,530
– –
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Tri Locum Partners held 37 positions worth $395M, up 37% from $288M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Tri Locum Partners deployed $91.9M of net new capital in Q2 2024, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Amgen: 82,271 shares worth $25.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $4.22M trimmed.

  • Tri Locum Partners's largest Q2 2024 buy was Amgen: 82,271 shares worth $25.7M.
  • Tri Locum Partners added most to Inspire Medical Systems in Q2 2024, an estimated $20.8M increase.
  • Tri Locum Partners's biggest Q2 2024 reduction was Xenon Pharmaceuticals, cutting an estimated $4.22M.
  • Tri Locum Partners fully exited Silk Road Medical, Inc. Common Stock in Q2 2024, selling an estimated $19.9M.
  • Tri Locum Partners's ten largest holdings make up 65% of its $395M portfolio in Q2 2024.
  • Tri Locum Partners opened 10 new positions and closed 12 in Q2 2024.
  • Tri Locum Partners's portfolio value rose 37% quarter-over-quarter to $395M.

Based on Tri Locum Partners's 13F filing for Q2 2024, filed 14 Aug 2024.